Talbot Financial LLC Buys 12,716 Shares of Medtronic PLC $MDT

Talbot Financial LLC raised its position in shares of Medtronic PLC (NYSE:MDT) by 7.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 190,722 shares of the medical technology company’s stock after purchasing an additional 12,716 shares during the quarter. Medtronic makes up approximately 1.5% of Talbot Financial LLC’s investment portfolio, making the stock its 26th largest holding. Talbot Financial LLC’s holdings in Medtronic were worth $18,164,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MDT. AXQ Capital LP boosted its position in shares of Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock valued at $862,000 after purchasing an additional 2,013 shares in the last quarter. Legacy Advisory Services LLC acquired a new stake in shares of Medtronic during the 1st quarter worth approximately $541,000. GC Wealth Management RIA LLC increased its stake in shares of Medtronic by 20.6% in the 2nd quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock valued at $2,926,000 after acquiring an additional 5,734 shares in the last quarter. Merit Financial Group LLC lifted its position in shares of Medtronic by 37.5% during the 2nd quarter. Merit Financial Group LLC now owns 57,035 shares of the medical technology company’s stock valued at $4,972,000 after acquiring an additional 15,561 shares during the period. Finally, Verdence Capital Advisors LLC boosted its stake in Medtronic by 22.0% during the second quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock worth $2,562,000 after acquiring an additional 5,296 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Up 0.2%

MDT stock opened at $98.54 on Friday. The firm has a market capitalization of $126.33 billion, a PE ratio of 26.56, a P/E/G ratio of 2.59 and a beta of 0.71. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic PLC has a twelve month low of $79.29 and a twelve month high of $106.33. The stock’s 50 day moving average is $97.32 and its 200-day moving average is $93.25.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.Medtronic’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Analyst Ratings Changes

MDT has been the subject of several research analyst reports. Wells Fargo & Company lifted their price target on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 target price on Medtronic and gave the company a “neutral” rating in a research report on Wednesday, November 19th. Cowen reaffirmed a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. UBS Group raised their price objective on Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Finally, Truist Financial decreased their price objective on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $109.94.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.